Amy Dezern, MD, MHS, presents the case of a 70-year-old man with myelodysplastic syndrome (MDS) and low ISSP-R, and reviews the best approaches for treatment of similar patients in clinical practice.
EP. 1: Case Presentation: A 70-Year-Old Man with Myelodysplastic Syndrome (MDS) and Low ISSP-R
Amy Dezern, MD, MHS, shares the case of a 70-year-old man with MDS stratified as low-risk using the Revised International Prognostic Scoring System.
EP. 2: Classification and Risk Stratification of MDS
Dr Amy Dezern discusses the criteria for subtype classification and risk stratification in patients with MDS.
EP. 3: Available First-Line Treatment Options for MDS
Amy Dezern, MD, MHS, describes the currently available first-line treatment options for patients with MDS.
EP. 4: The Importance of Early Frontline Treatment Initiation for Patients With MDS
Dr Amy Dezern emphasizes how delayed frontline treatment of MDS can impact overall outcomes for patients with MDS.
EP. 5: Treating MDS with Erythropoiesis-Stimulating Agents (ESAs)
Amy Dezern, MD, MHS, details her experience with using erythropoiesis stimulating agents for the treatment of MDS in her clinical practice.
EP. 6: Rationale for Treatment of MDS With Luspatercept
Dr Amy Dezern reviews the mechanism of action of luspatercept and its rationale for use in MDS.
EP. 7: Dose Titration of Luspatercept in Patient With MDS
Amy Dezern, MD, MHS, explains the importance of proper dose titration for luspatercept in the treatment of MDS.
EP. 8: Luspatercept as a First-Line Treatment for Patients With Lower-Risk MDS
Dr Amy Dezern discusses the FDA priority review for luspatercept in the first-line setting for MDS and how it may impact patients.
EP. 9: Unmet Needs in the Treatment of Patients With MDS
Amy Dezern, MD, MHS, closes her discussion by emphasizing the need for more treatments in MDS.
2 Clarke Drive Cranbury, NJ 08512